

Edgar Filing: CRYOLIFE INC - Form 5

CRYOLIFE INC
Form 5
February 12, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 5

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

() Check box if no longer subject to Section 16.

Form 4 or Form 5 obligations may continue. See Instructions 1(b).

() Form 3 Holdings Reported

() Form 4 Transactions Reported

1. Name and Address of Reporting Person

FRONK, DAVID

c/o CryoLife, Inc.

1655 Roberts Blvd., NW

Kennesaw, GA 30144

USA

2. Issuer Name and Ticker or Trading Symbol

CRYOLIFE, INC.

CRY

3. IRS or Social Security Number of Reporting Person (Voluntary)

4. Statement for Month/Year

12/31/2001

5. If Amendment, Date of Original (Month/Year)

6. Relationship of Reporting Person(s) to Issuer (Check all applicable)

() Director () 10% Owner (X) Officer (give title below) () Other

(specify below)

Vice President - Clinical Research

7. Individual or Joint/Group Reporting (Check Applicable Line)

(X) Form filed by One Reporting Person

() Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security | 2. Transaction Date | 3. Code | 4. Securities Acquired (A) or Disposed of (D) Amount | 5. Amount of Securities Beneficially Owned at End of Year |
|----------------------|---------------------|---------|---|---|
| Common Stock | | | | 2,240 (1) |

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Derivative Security | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date | 4. Code | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) Amount | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities Title and Number of Shares | 8. Percentage of Total Ownership |
|---------------------------------|--|---------------------|---------|--|--|--|----------------------------------|
| | | | | | | | |

Edgar Filing: CRYOLIFE INC - Form 5

| | | | | | | | | | | |
|------------------------|----------|-------|---|-------|---|-----|-------|--------------|-------|-----|
| Incentive Stock Option | \$30.856 | 5-17- | A | 8,768 | A | (2) | 11-17 | Common Stock | 8,768 | N/A |
| | | 01 | | | | | -06 | | | |

| | | | | | | | | | | |
|-----------------------------|----------|-------|---|--------|---|-----|-------|--------------|--------|-----|
| Non-qualifying Stock Option | \$30.856 | 5-17- | A | 12,232 | A | (3) | 11-17 | Common Stock | 12,232 | N/A |
| | | 01 | | | | | -06 | | | |

Explanation of Responses:

(1) Includes 466 shares acquired under the CryoLife, Inc. stock purchase plan during 2001.

(2) Option vests as follows: 350 shares on first anniversary of grant date; 350 shares on second anniversary of grant date; 1,588 shares on third anniversary of grant date; 3,240 shares on fourth anniversary of grant date; 3,240 shares on fifth anniversary of grant date.

(3) Option vests annually in 20% increments over five years beginning on first anniversary of grant date.

SIGNATURE OF REPORTING PERSON

/s/ David Fronk

DATE

February 11, 2002